Axim Biotechnologies Stock Performance
| AXIM Stock | USD 0 0.0001 3.23% |
Axim Biotechnologies holds a performance score of 7 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.37, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Axim Biotechnologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Axim Biotechnologies is expected to be smaller as well. Use Axim Biotechnologies total risk alpha and the relationship between the potential upside and day typical price , to analyze future returns on Axim Biotechnologies.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Axim Biotechnologies are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile forward indicators, Axim Biotechnologies displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 457.2 K | |
| Total Cashflows From Investing Activities | -50.5 K |
Axim |
Axim Biotechnologies Relative Risk vs. Return Landscape
If you would invest 0.20 in Axim Biotechnologies on December 23, 2024 and sell it today you would earn a total of 0.10 from holding Axim Biotechnologies or generate 50.0% return on investment over 90 days. Axim Biotechnologies is currently generating 1.5305% in daily expected returns and assumes 15.4052% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Axim, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Axim Biotechnologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Axim Biotechnologies' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Axim Biotechnologies, and traders can use it to determine the average amount a Axim Biotechnologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0994
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | AXIM | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.41 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.53 actual daily | 30 70% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Axim Biotechnologies is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Axim Biotechnologies by adding it to a well-diversified portfolio.
Axim Biotechnologies Fundamentals Growth
Axim Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Axim Biotechnologies, and Axim Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Axim Pink Sheet performance.
| Return On Equity | -100.19 | |||
| Return On Asset | -0.35 | |||
| Operating Margin | (847.86) % | |||
| Current Valuation | 13.6 M | |||
| Shares Outstanding | 186.44 M | |||
| Price To Earning | (53.71) X | |||
| Price To Book | 2.86 X | |||
| Price To Sales | 943.93 X | |||
| Revenue | 60.46 K | |||
| EBITDA | (13.42 M) | |||
| Cash And Equivalents | 65.16 K | |||
| Total Debt | 5.06 M | |||
| Debt To Equity | 1.36 % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (2.49 M) | |||
| Earnings Per Share | (0.13) X | |||
| Total Asset | 5.32 M | |||
| Retained Earnings | (36.37 M) | |||
| Current Asset | 1.18 M | |||
| Current Liabilities | 2.55 M | |||
About Axim Biotechnologies Performance
By examining Axim Biotechnologies' fundamental ratios, stakeholders can obtain critical insights into Axim Biotechnologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Axim Biotechnologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California. Axim Biotechnologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.Things to note about Axim Biotechnologies performance evaluation
Checking the ongoing alerts about Axim Biotechnologies for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Axim Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Axim Biotechnologies is way too risky over 90 days horizon | |
| Axim Biotechnologies has some characteristics of a very speculative penny stock | |
| Axim Biotechnologies appears to be risky and price may revert if volatility continues | |
| Axim Biotechnologies has high likelihood to experience some financial distress in the next 2 years | |
| Axim Biotechnologies currently holds 5.06 M in liabilities with Debt to Equity (D/E) ratio of 1.36, which is about average as compared to similar companies. Axim Biotechnologies has a current ratio of 0.06, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Axim Biotechnologies until it has trouble settling it off, either with new capital or with free cash flow. So, Axim Biotechnologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Axim Biotechnologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Axim to invest in growth at high rates of return. When we think about Axim Biotechnologies' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 60.46 K. Net Loss for the year was (16.03 M) with profit before overhead, payroll, taxes, and interest of 60.46 K. | |
| Axim Biotechnologies currently holds about 65.16 K in cash with (2.49 M) of positive cash flow from operations. | |
| Roughly 41.0% of Axim Biotechnologies shares are held by company insiders |
- Analyzing Axim Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Axim Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Axim Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Axim Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Axim Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Axim Biotechnologies' pink sheet. These opinions can provide insight into Axim Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Axim Pink Sheet
Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.